The risks and benefits of indacaterol--the FDA's review

N Engl J Med. 2011 Dec 15;365(24):2247-9. doi: 10.1056/NEJMp1109621.

Authors

Badrul A Chowdhury¹, Sally M Seymour, Theresa M Michele, Anthony G Durmowicz, Dongmei Liu, Curtis J Rosebraugh

Affiliation

¹ Division of Pulmonary, Allergy, and Rheumatology Products, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.

PMID: 22168640
DOI: 10.1056/NEJMp1109621

No abstract available

MeSH terms

Administration, Inhalation
Adrenergic beta-2 Receptor Antagonists / administration & dosage*
Adrenergic beta-2 Receptor Antagonists / adverse effects
Asthma / chemically induced
Asthma / drug therapy*
Dose-Response Relationship, Drug
Drug Approval*
Drug Evaluation / methods
Humans
Indans / administration & dosage*
Indans / adverse effects
Pulmonary Disease, Chronic Obstructive / drug therapy
Quinolones / administration & dosage*
Quinolones / adverse effects
United States
United States Food and Drug Administration

Substances

Adrenergic beta-2 Receptor Antagonists
Indans
Quinolones
indacaterol